Yalcintepe, SinemGurkan, HakanDogan, Ipek GungorDemir, SelmaSag, Sebnem OzemriKabayegit, Zehra ManavAtli, Emine Ikbal2024-06-122024-06-1220211019-5149https://doi.org/10.5137/1019-5149.JTN.33661-21.3https://hdl.handle.net/20.500.14551/19688AIM: To investigate the genetic etiology of Charcot-Marie-Tooth (CMT) disease or hereditary motor and sensory neuropathy (HMSN). MATERIAL and METHODS: We herein examined 55 non-related patients with a suspicion of CMT phenotype or HMSN using a customized multigene panel based on the next-generation sequencing technique. All cases were previously analyzed for PMP22 duplication with the Multiplex Ligand Probe Amplification (MLPA) method. RESULTS: In 13 cases (7.15%), we identified a pathogenic/likely pathogenic variant. The affected genes were MARS1, NDRG1, GJB1, GDAP1, MFN2, PRX, SH3TC2, and FGD4. In six cases (10.9%), novel variants were identified: pathogenic variants in GJB1 and FGD4 genes, variants of unknown significance (VUS) in HSPB3, CHRNA1, ARHGEF10, and KIF5A genes. In 21 cases (11.55%), VUS with the genes HSPB3, KIF1B, SCN11A, CHRNA1, HSPB1, FIG4, ARHGEF10, DHTKD1, SBF1, EGR2, SBF2, IGHMBP2, KIF5A, and DNAJB2 were identified. CONCLUSION: In this study, we had a 7.15% diagnosis rate with the NGS (Next Generation Sequencing) method in the CMT disease. Targeted next-generation sequencing panels are beneficial, time-saving, and cost-effective in the diagnosis of CMT.en10.5137/1019-5149.JTN.33661-21.3info:eu-repo/semantics/openAccessCharcot-Marie-ToothNext Generation SequencingMultigene TestingHereditary NeuropathyDistal Symmetric PolyneuropathyNeuropathiesAssociationMpzArticle316888895Q4WOS:0007267943000092-s2.0-8512005715934169998Q3